SCHEMBL311610

SCHEMBL311610

COc1cc(C=O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.67
CA2 P00918 1/20 0.67
ERN1 O75460 15/20 0.50
TRIM24 O15164 1/20 0.46
TYR P14679 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
EGFR P00533 1/20 0.45
GABBR2 O75899 1/20 0.41
GABBR1 Q9UBS5 1/20 0.41
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186532 1.00 CA1 (0.67) CA1CA2ERN1TRIM24TYR
SCHEMBL7285302 0.83 ERN1 (0.62) ERN1TRIM24TYRTRIM33ALDH1A1
SCHEMBL39130 0.81 CA2 (1.00) CA1CA2TYREGFRMEN1
SCHEMBL18157017 0.81 ELANE (0.45) CA1CA2ERN1GABBR2GABBR1
SCHEMBL27709448 0.81 CA1 (0.48) CA1CA2ERN1TRIM24TYR
SCHEMBL6446758 0.81 ERN1 (0.45) CA1CA2ERN1TRIM24TYR
SCHEMBL544833 0.79 CA1 (0.56) CA1CA2TYREGFRGABBR2
SCHEMBL544834 0.79 CA1 (0.56) CA1CA2ERN1EGFRGABBR2
SCHEMBL5633091 0.79 CA2 (0.40) CA1CA2ERN1TYRGABBR2
SCHEMBL30222051 0.78 ERN1 (0.47) CA1CA2ERN1TYRGABBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109675634-A The preparation method and application of heterogeneous Schiff base catalyst 昆明理工大学 2019-04-26 CN claimed
US-11260379-B2 Catalysts and methods for epoxide-based polymerizations CORNELL UNIVERSITY (US) 2022-03-01 US disclosed
US-20210394166-A1 CATALYST COMPOSITION UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) 2021-12-23 US disclosed
US-20200384450-A1 CATALYSTS AND METHODS FOR EPOXIDE-BASED POLYMERIZATIONS CORNELL UNIVERSITY 2020-12-10 US disclosed
US-20200384450-A1 CATALYSTS AND METHODS FOR EPOXIDE-BASED POLYMERIZATIONS CORNELL UNIVERSITY 2020-12-10 US disclosed
CN-109675634-A The preparation method and application of heterogeneous Schiff base catalyst 昆明理工大学 2019-04-26 CN disclosed
US-9200100-B2 Long-bridged salen catalyst EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-12-01 US disclosed
US-20140378633-A1 Long-Bridged Salen Catalyst EXXONMOBIL CHEMICAL PATENTS INC. 2014-12-25 US disclosed
WO-2014204681-A1 LONG-BRIDGED SALEN CATALYST EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-12-24 WO disclosed
US-8093349-B2 Terminally modified polybranched polyimide, metal-plated terminally modified polybranched polyimide, and method for producing the same UBE INDUSTRIES, LTD. (JP) 2012-01-10 US disclosed
EP-1066228-A1 PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2001-01-10 EP disclosed
EP-1013674-A1 Olefin polymerization catalyst and process for olefin polymerization using this catalyst Mitsui Chemicals, Inc. (JP) 2000-06-28 EP disclosed
WO-1999051546-A9 PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF HARVARD COLLEGE (US) 1999-11-18 WO disclosed
WO-1999051546-A1 PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1999-10-14 WO disclosed
EP-0390682-B1 Cosmetic and pharmaceutical compositions containing hydrophilic derivatives of benzylidene camphor and sulfonated hydrophilic derivatives of benzylidene camphor OREAL (FR) 1994-06-22 EP disclosed
EP-0390683-B1 Benzyl-cyclanones derivatives, process for their preparation and cosmetic and pharmaceutical compositions containing them OREAL (FR) 1993-10-27 EP disclosed
US-5223533-A Antiallergens, antiinflammatory, sunscreen agents L'OREAL (FR) 1993-06-29 US disclosed
US-5000961-A Tert-butyl derivatives of benzylidenecamphor, process for preparing them, their use as antioxidant agents and cosmetic and pharmaceutical compositions containing them L'OREAL (FR) 1991-03-19 US disclosed
EP-0390682-A1 Cosmetic and pharmaceutical compositions containing hydrophilic derivatives of benzylidene camphor and sulfonated hydrophilic derivatives of benzylidene camphor L'OREAL (FR) 1990-10-03 EP disclosed
US-4952391-A SUNSCREEN AGENT L'OREAL (FR) 1990-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210394166-A1 CATALYST COMPOSITION MLX, MICOS13, KMO CA1 1758/4885CA2 2509/4885ERN1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.